Trypanocidal drugs: mechanisms, resistance and new targets.
about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisA new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imagingBromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African TrypanosomeThe crystal structure of Leishmania major N5,N10-methylenetetrahydrofolate dehydrogenase/cyclohydrolase and assessment of a potential drug targetBiological and Structural Characterization of Trypanosoma cruzi Phosphodiesterase C and Implications for Design of Parasite Selective InhibitorsIdentification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaignTrypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell deathMolecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetaseHighly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferaseA quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruziHigh throughput screening for anti-Trypanosoma cruzi drug discoveryAutomated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell lineGenome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6.High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome.Megazol and its bioisostere 4H-1,2,4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme.Heme-induced ROS in Trypanosoma cruzi activates CaMKII-like that triggers epimastigote proliferation. One helpful effect of ROSCryo-electron tomography and 3-D analysis of the intact flagellum in Trypanosoma brucei.Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic trypanosomatidsTargeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.Evaluating 5-nitrofurans as trypanocidal agents.Proteomics on the rims: insights into the biology of the nuclear envelope and flagellar pocket of trypanosomes.Genetic dissection of drug resistance in trypanosomesCyclical appearance of African trypanosomes in the cerebrospinal fluid: new insights in how trypanosomes enter the CNS.Biological targets and mechanisms of action of natural products from marine cyanobacteria.Discovery of new uncompetitive inhibitors of glucose-6-phosphate dehydrogenase.Antiparasitic chemotherapy: from genomes to mechanisms.Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Characterization of the M32 metallocarboxypeptidase of Trypanosoma brucei: differences and similarities with its orthologue in Trypanosoma cruzi.Temporizin and Temporizin-1 Peptides as Novel Candidates for Eliminating Trypanosoma cruzi.Characterization of 2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl Ureido Based Inhibitors of Trypanosoma brucei FolD and Testing for Antiparasitic ActivityTrypanosoma cruzi antioxidant enzymes as virulence factors in Chagas disease.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.DNA repair pathways in trypanosomatids: from DNA repair to drug resistance.Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.Trypanosoma cruzi-Derived Neurotrophic Factor: Role in Neural Repair and Neuroprotection.Drug resistance in human African trypanosomiasis."Drug resistance associated membrane proteins".Evaluating 5-Nitrothiazoles as Trypanocidal Agents.
P2860
Q21144510-EE1E9A57-CC0F-4429-9C20-EEE15EB4903AQ27011506-C7F78319-D6F1-49F3-B6C5-E370FFFABF1FQ27345564-B30BBEC3-E212-4510-8A0B-6523B6E04AE2Q27675760-DCC44FB9-ED64-47A6-8D2F-FB315CC33600Q27677423-DFE90D21-2636-4D5B-81C0-7D5E8D985AF3Q28485372-E91FDD56-137E-400E-8D21-D0C24FA9570BQ28485411-D9944580-8926-496F-AF9F-955400D436D5Q28486718-EC2E2E20-D174-40F2-8773-57FF1721F47AQ28535374-DABB04F3-A940-4020-AE8A-E4A67BD91E9AQ28538813-49EB9EFA-3B56-46EA-BF76-FA69615177D7Q28542489-CDC35094-BFA4-40C1-98A3-9CD83D7FE98CQ28543069-753E5433-74B8-4297-873A-A244FB96CD74Q30992269-730C69D3-61C3-4968-A66F-34F723364AD8Q33833378-B2D9ACA5-6D9C-46E9-89E4-997B303DC35AQ34040586-DEE13003-4249-45C6-9F85-E4184900FB99Q34055820-D9D443DE-BD4F-418B-AF62-5ECACF531B3AQ34143711-1CF46D76-5FDE-4A9B-B391-AD6A97C64AAAQ34272471-3D120EE8-30F5-4CC7-AEB3-5C6DB4FEDF1EQ34403287-6601CB7C-BC01-441F-9931-AC07C3843F1DQ34555495-6FF99250-2DFD-49BF-BD6E-F0C9381A5F61Q34562107-FE5B86CA-D470-4077-B1F5-29DCFD52440DQ34647009-CE5A11EF-61D6-4618-9BD7-DE0736749756Q35117720-68C88551-D050-4DB7-B887-44740201CE06Q35130835-D2AB887E-8BDA-421A-A436-26B20E1607E8Q35224409-951A360F-AD95-4196-9D39-095908CA40EDQ35238319-3784327B-35F7-468B-83C5-E4CF22BC7FEEQ35859935-C68C90F1-AE27-48BA-AD2F-9FAA83328F24Q36059069-A5A4D0CA-DEB5-48E0-9062-AA802099D331Q36069187-C8F75E83-F92E-4045-A446-F3E01E4266B4Q36209502-6D37F4B7-D5DC-4505-90F8-F08C2AF738BEQ37086096-7885440A-2D15-49DC-B58E-CD0A29A3FD3AQ37309281-4825AA38-999E-4DB6-A0C9-75909475A920Q37342932-04AB8A9B-6DF8-4679-A34F-BDB45FF6E681Q37449692-7F53CF92-E7AB-4A53-9A67-A94EE119A763Q37643441-7C107F81-DB39-42E9-82E1-99EB5BCAAEBFQ37856305-AA48552E-989C-45B9-A5F4-8ACA6C482A90Q37875699-7AC028AD-954C-468A-9DF1-8DD9D0BD0A25Q37940573-6418EA4F-19EB-4C30-8BEC-5B4E2EF8CA0EQ38366599-B422535E-99E7-424B-9B94-A47C37C3276FQ38367643-88BA2F4C-25C6-484D-9463-D2B860596C77
P2860
Trypanocidal drugs: mechanisms, resistance and new targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trypanocidal drugs: mechanisms, resistance and new targets.
@en
Trypanocidal drugs: mechanisms, resistance and new targets.
@nl
type
label
Trypanocidal drugs: mechanisms, resistance and new targets.
@en
Trypanocidal drugs: mechanisms, resistance and new targets.
@nl
prefLabel
Trypanocidal drugs: mechanisms, resistance and new targets.
@en
Trypanocidal drugs: mechanisms, resistance and new targets.
@nl
P2860
P1476
Trypanocidal drugs: mechanisms, resistance and new targets.
@en
P2093
John M Kelly
Shane R Wilkinson
P2860
P356
10.1017/S1462399409001252
P5008
P577
2009-10-29T00:00:00Z